CP and cancer: As CP is a novel serum biomarker for PJI that at the time this study was conducted, had not been investigated before, it was tried to minimize possible influencing factors, even though it is known that especially elderly patients that require revision arthroplasty may have relevant comorbidities such as malignant tumors or other infections.